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AbstrACt
Introduction Patellofemoral pain (PFP) affects 1 in 
every 14 adults. Many treatments for PFP have been 
evaluated, but the comparative effectiveness of all 
available treatments has never been examined. Network 
meta-analysis is the only design to study the comparative 
effectiveness of all available treatments in one synthesis. 
This protocol describes the methods for a systematic 
review including network meta-analysis to assess which 
treatment is most likely to be effective for patients with 
PFP.
Methods and analysis The primary outcome measures 
of this network meta-analysis are the global rating of 
change scale at 6–12 weeks, 13–52 weeks and >52 
weeks. The secondary outcome measures are patient-
rated pain scales at 6–12 weeks, 13–52 weeks and >52 
weeks. Completed published and unpublished randomised 
controlled trials with full-text reports are eligible for 
inclusion. We will search Embase, PubMed (including 
MEDLINE), CENTRAL, Scopus, Web of Science, and 
CINAHL, SPORTDiscus, OpenGrey, WorldCat, conference 
Proceedings and multiple trial registers for relevant 
reports. Two researchers will appraise the study eligibility 
and perform data extraction. Risk of bias will be assessed 
with the Cochrane Risk of Bias Tool V.2.0. Bayesian 
network meta-analyses will be constructed for global 
rating of change scale and patient-rated pain. Consistency 
between direct and indirect comparisons will be assessed. 
Between study variability will be explored, and a threshold 
analysis for the credibility of the network meta-analyses’ 
conclusions will be performed.
Ethics and dissemination Ethical approval is not 
required, as this study will be based on published 
data. The study commenced at 1 February 2018, and 
its expected completion date is 15 January 2019. Full 
publication of the work will be sought in an international 
peer-reviewed journal, as well as translational articles to 
disseminate the work to clinical practitioners.
PrOsPErO registration number CRD42018079502.
IntrOduCtIOn 
Patellofemoral pain (PFP) affects 1 in every 
14 adolescents and 1 in every 8 adults.1 PFP 
is characterised by diffuse pain around or 
behind the knee cap, provoked during activ-
ities that load the knee-joint, such as stair 
climbing, running and jumping.2 One in 
every two patients with PFP continue to suffer 
from knee pain, which can impact their 
quality of life and physical activity.3 4 
Similar to other chronic musculoskeletal 
pain conditions, there are many different 
treatments. Recent recommendations 
from an expert panel based on the avail-
able evidence are for the use of exercise of 
the hip and knee, foot orthoses and combi-
nations that include patellar taping or 
manual therapy.5 Patient education and gait 
retraining have been recently promoted as 
well but with little research support.5 6 While 
there are several systematic reviews that 
focus on different treatments for PFP,7–12 
the comparative effectiveness of all available 
treatments has never been examined. This is 
challenging for clinicians and patients who 
are faced with uncertainty when presented 
with so many potentially beneficial treatment 
options.
strengths and limitations of this study
 ► This living systematic review will include thorough 
search methods, searching conventional databases, 
grey literature resources and trial registers.
 ► Risk of bias in randomised controlled trials will be 
appraised using the new Cochrane Risk of Bias tool 
V.2.0 for intervention studies.
 ► This living systematic review and network me-
ta-analysis enables clinicians to consult a contem-
porary, comprehensive overview of the comparative 
effectiveness of treatments for patellofemoral pain.
 ► The feasibility of this study is depending on the 
availability and the homogeneity of the trials and the 
consistency between direct and indirect evidence.
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Traditional systematic reviews present fragmented pair-
wise ‘head to head’ comparisons, for example, treatment 
A versus B, and treatment B versus C. The limitation 
with this approach is that multiple treatments cannot be 
compared simultaneously (ie, treatment A vs B vs C). The 
traditional approach may lead to invalid interpretations 
regarding the comparative effectiveness of treatments.13 
Clinicians are left to speculate on which treatment is most 
effective, based on multiple, independent ‘head to head’ 
comparisons. Network meta-analyses offer the oppor-
tunity to combine both direct and indirect treatment 
comparisons in a single analysis, which overcomes main 
limitations of pairwise systematic reviews. They do this by 
allowing for:
 ► A coherent comparison of effectiveness of multiple 
treatments in one statistical model while maintaining 
the randomised nature of the evidence.
 ► Comparison of treatments even if the treatments 
have not been investigated directly in a randomised 
controlled trial (RCT).14–16
Based on the network meta-analysis (NMA), a ranking 
from ‘most likely to be effective’ to ‘least likely to be effec-
tive’ treatment (for a given outcome) can be estimated. 
In this way, the results from the NMA can directly feed 
into shared decision making in clinical practice.
A common critique on systematic reviews is that they 
are soon out of date.17 Living NMAs are particularly suit-
able to control for this issue as they are regularly updated, 
preferably as open access content. This enables clinicians 
to consult a comprehensive overview of the comparative 
effectiveness of treatments for a given condition, while 
ensuring a contemporary evidence synthesis for clinical 
practice (table 1).18 19
The comparative effectiveness of all studied treat-
ments for patients with PFP has never been examined. 
The aim of this living systematic review with NMA is to 
evaluate the comparative effectiveness of all available 
treatments for patients with PFP, providing a compre-
hensive and up-to-date overview of evidence-based 
treatments.
MEthOds
Protocol registration
The protocol for this living systematic review with 
NMA is registered on PROSPERO (CRD42018079502). 
This protocol follows the Preferred Reporting Items 
for Systematic Review and Meta-Analysis Protocols and 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses extension for NMA checklist for reporting 
systematic review protocols and NMA.20–22
Patient involvement and prioritising outcomes
Patients with PFP (n=7) from a patient reference group 
have been involved in setting a hierarchy of outcomes 
(global rating of change scale (GROC) and pain scales) 
for this NMA. One researcher, otherwise not involved in 
the study (see acknowledgements), contacted the patient 
panel members by phone. He explained the various 
outcomes. All participants were subsequently sent a list 
and asked to indicate the most relevant instrument to 
judge their knee pain. Six out of seven (86%) indicated 
a preference for the GROC over pain outcomes. Conse-
quently, the outcomes selected are as follows:
Primary outcome measure
 ► GROC: this scale usually has seven descriptors for 
perceived change: completely recovered, strongly 
recovered, slightly recovered, unchanged, slightly 
worse, strongly worse and worse than ever. The relia-
bility of the GROC is excellent with intraclass correla-
tion coefficient (ICC) from 0.90 to 0.99.23 24
secondary outcome measures
 ► Pain intensity, measured by ‘worst pain in the previous 
week’ on a visual analogue scale (VAS) (0–10/0–100) 
or numerical rating pain scale (NRPS) (0–10/0–100). 
The reliability is excellent, ICC=0.76.24 25
 ► Patient-rated pain during specific activities of daily life 
(ADLs) and during sporting activities. We will synthe-
sise one pain outcome for ADL and one for sporting 
activities. The choice for these outcomes will be made 
based on availability, an outcome that allows for inclu-
sion of the highest number of comparisons. Pain will 
Table 1 The advantages of a living network meta-analysis (NMA) compared with traditional systematic reviews
Traditional systematic 
review+meta-analysis Systematic review+NMA Living systematic review+NMA
Direct comparison between treatments X X X
Indirect comparisons between treatments that have 
never been compared in an RCT
X X
Research question
 ► Which treatment is most effective: A or B?
 ► Which of the many available treatments that 
have been tested in randomised trials are most 
effective?
X X
X
X
X
Always up-to-date best evidence synthesis to inform 
clinical practice
X
RCT, randomised controlled trial.
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be expressed a VAS (0–10/0–100) or NRPS (0–10/0–
100). Reliability for pain during activity is excellent, 
ICC=0.83.24 25
research questions
1. Which treatment(s) is most likely to be effective for 
patients with PFP on global rating of change and pa-
tient-rated pain?
2. Which treatment class(es) is most likely to be effective 
for patients with PFP on global rating of change and 
patient-rated pain? The study of treatment classes is 
relevant when more than one subtype for a treatment 
is available, for example, multiple types of exercise re-
gimes, which can be grouped together to answer this 
question.
Eligibility criteria
Type of studies
Published or unpublished RCTs (including randomis-
ation through minimisation or clustering), for which a 
full-text report or full-text protocol of a completed trial is 
available, are eligible for inclusion.
Type of population
All patients with a clinical diagnosis of PFP are 
included. Studies will be included if they use synonyms 
for PFP, but as minimum criterion, should describe 
patients with retropatellar or peripatellar pain, of at 
least 6 weeks’ duration and a non-traumatic onset. 
The diagnostic criteria used in the original studies will 
be followed, given that the aforementioned minimal 
diagnostic criteria are met. Studies examining other 
conditions are excluded (eg, patellar dislocations, 
patellofemoral osteoarthrosis, patellar tendinopathy, 
Osgood-Schlatter, iliotibial band syndrome and Sind-
ing-Larsen-Johansson syndrome). Trials that include 
participants diagnosed with PFP, but with concomitant 
pain around the patella caused by other conditions 
(eg, patellar tendinopathy) will be considered eligible 
for inclusion. No age restrictions will be imposed.
Type of treatments and control treatments
Any treatment, control treatment, placebo, wait-and-see 
or no treatment group studied in an RCT is eligible for 
inclusion. Examples of treatment classes are exercise 
therapy, orthoses, braces, patient education, pain medi-
cine or surgery.
Type of outcomes
Studies assessing the treatment effect after a minimum of 
6 weeks will be included. Studies assessing the following 
outcomes will be included:
 ► GROC.
 ► Worst pain in the previous week, measured with a VAS 
(0–10) or NRPS (0–100).
 ► Patient-rated pain during activities of daily living and 
sporting activities, measured with a VAS (0–10) or 
NRPS (0–100).
search strategy
A sensitive search strategy has been developed for each 
of the data sources by a research librarian and one inves-
tigator (MW). We used the Cochrane sensitive search 
strategy for RCTs and modified this for the purpose of 
our study.26 The search strategy includes a mix of indexed 
and free text terms, where applicable (online supplemen-
tary appendix 1). No restrictions (eg, language or full-text 
availability) were applied to the search.
One investigator (MW) will search conventional data-
bases, grey literature databases and trial registers from 
their date of inception. Online supplementary appendix 
1 provides a detailed explanation of how the search is 
built and with source-specific search strategies for each 
database, grey literature sources and trial registers.
Conventional databases
Conventional electronic databases Embase, PubMed 
(including MEDLINE), Cochrane Central Register of 
Controlled Trials (CENTRAL), Scopus, Web of Science, 
and CINAHL and SPORTDiscus (both via EBSCO) will be 
searched for relevant reports.
Identifying grey literature and ongoing studies
Databases
 OpenGrey. eu and  WorldCat. org will be searched for 
studies that have remained unpublished.
Conference proceedings
We will search the conference proceedings from all 
Patellofemoral Research Retreats (2009, 2011, 2013, 2015 
and 2017) for relevant reports and request authors to 
make available their full reports or protocols for unpub-
lished studies.
Trial registers
We will search the WHO International Clinical Trials 
Registry Platform (http:// apps. who. int/ trialsearch/) 
ClinicalTrials. gov, The European Union Clinical Trials 
Register and the ISRCTN registry for unpublished or 
ongoing studies.
Hand searching
We will screen reference lists of all Cochrane reviews 
(n=6) on PFP for possible relevant studies that were not 
identified by our search. We will also screen reference 
lists of all the reports included in our systematic review.
study selection
Two researchers will screen titles and abstracts inde-
pendently, after duplicate removal by one of the inves-
tigators. Consensus will be sought in case of initial 
disagreement. If consensus cannot be reached, the report 
will be included for full-text evaluation.
Both investigators will independently apply inclusion 
and exclusion criteria to the full-text reports. In case 
of disagreement, consensus will be sought; however, if 
disagreement persists, a third author (AW) will take the 
decision.
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data extraction
Data will be independently extracted by two researchers 
using standardised extraction forms adopted from 
the Cochrane Collaboration (see online supplemen-
tary appendix 2).27 Disagreements will be resolved by 
seeking consensus and by a third reviewer (AW) in case 
of persistent disagreement. The following data will be 
extracted:
 ► Publication and study details: for example, authors, 
year of publication, funding source, possible conflicts 
of interest, aim study, design and unit of allocation.
 ► Population: number of included patients, population 
characteristics for age, sex, body mass index, activity 
level, setting where population was recruited, base-
line scores for outcome measures (mean, SDs, SEs 
extracted for continuous outcomes, and number and 
percentage for categorical outcomes).
 ► Eligibility criteria and diagnostic criteria used for PFP.
 ► Treatments: for example, number randomised to 
group, detailed description of, for example, applica-
tion, dose, intensity, frequency, number of sessions, 
delivery, tailoring (individual/group), duration of 
treatment, providers, cotreatments, modification 
(change to treatment) and adherence. We used 
items from the Template for Intervention Descrip-
tion and Replication checklist to assure comprehen-
sive data extraction in this section of the extraction 
form.28
 ► Outcomes: time points measured, and the time points 
reported on, outcome definition, person measuring, 
unit of measurement, scales (upper and lower limits), 
imputation of missing data, primary and secondary 
outcomes used in the original trials, unintentional 
outcomes (eg, adverse events, adverse effects and side 
effects).
 ► Data and analysis: comparisons, outcomes, subgroups, 
time points, results (central estimates and measures of 
dispersion; for example, mean for both groups, mean 
difference (MD), SDs/95% CIs/SEs), number of 
missing patients, statistical methods used and appro-
priateness of these.
 ► Other information: key conclusions of study authors.
risk of bias assessment
The Cochrane Risk of Bias Tool 2.0 will be used to 
assess the risk of bias for each outcome per study and 
for outcomes across a (direct) comparison. In this tool 
risk of bias can be assessed following the ‘intention-to-
treat’ principle (ie, assignment to intervention) or ‘per 
protocol’ (ie, adherence to intervention). We will assess 
risk of bias on the basis of ‘assignment to intervention’. 
This new tool has a fixed set of items to use for the risk 
of bias appraisal, that is, ‘bias arising from the random-
ization process’, ‘bias due to deviations from intended 
interventions’, ‘bias due to missing outcome data’, ‘bias 
in measurement of the outcome’, ‘bias in selection of the 
reported result’ and overall risk of bias judgement for 
each outcome.29 30
Two experienced reviewers will independently assess 
the risk of bias for each outcome within the study for 
each follow-up. They will trial the approach by assessing 
20 RCTs in other musculoskeletal conditions, before the 
study starts. Each major domain of bias will be appraised 
in light of each outcome. The tool’s signalling questions 
and criteria will be followed to inform a domain-based 
appraisal of the risk of bias.29 30 The risk of distortion 
of the outcome estimate by the methodology will be 
appraised as at ‘low’, ‘some’ or ‘high’ risk of bias. Judge-
ments will be made regarding the direction of distortion 
‘favours experimental’, ‘favours comparator’, ‘towards 
null’, ‘away from null’ or ‘unpredictable’. Each outcome 
within a study will receive an overall risk of bias judge-
ment based on the individual domains: ‘low’, ‘some’ or 
‘high’ risk of bias.29 30
In case of disagreements between reviewers, consensus 
will be sought through discussions. If consensus is not 
met, a third reviewer (AW) will take the decision.
data synthesis and statistical methods
We plan a NMA to assess which treatment for PFP is 
most effective. Networks of treatment comparisons will 
be constructed for the primary and (each) secondary 
outcome separately.
Three authors (MW, SH and MSR) will appraise the 
clinical homogeneity before any analysis is commenced 
by tabulating study and population characteristics and 
inspecting them for differences in potential effect modi-
fiers. This is to assess the assumption of exchangeability 
required for NMA. In addition, treatments will be assigned 
to a class, for example, exercise therapy, surgery and drug 
therapy.
Bayesian NMA
We will model networks following the Bayesian approach, 
using Markov chain Monte Carlo simulations in WinBUGS 
(V.1.4, Medical Research Council, UK, and Imperial 
College of Science, Technology and Medicine, University 
of Cambridge, UK). Direct, pair-wise comparisons will 
be estimated first. For treatments that are connected in 
a network of comparisons from our included studies, we 
will estimate relative treatment effects using NMA, and 
hierarchical NMA using classes if possible.31 32
Our primary outcome measure, the GROC, will 
be synthesised using a proportional odds model and 
expressed with an OR and their 95% credible interval, 
if GROCs across studies are similar. Otherwise, GROCs 
will be dichotomised at a common cut-off point where all 
scales coincide, for example, improved/not improved, 
recovered/not recovered. In the latter case, a logistic 
regression model will be run.
For our secondary outcome measures, continuous 
outcomes will be presented as MD, with their 95% cred-
ible intervals when outcomes are measured with the same 
instrument. We will present standardised MDs if different 
continuous measures are used to evaluate the same 
construct.
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For all analyses, we will fit both fixed and random effects 
models and compare model fit using the deviance infor-
mation criterion and posterior mean residual deviance. A 
lower deviance depicts a better model fit. We will group 
outcome follow-ups based on the available data, seeking 
the following approximate timeframes: 6–12 weeks, 13–52 
weeks and >52 weeks. If there are multiple time points 
available for an outcome, and these are equally close to 
the time point to be synthesised across studies, the last 
follow-up in this timeframe will be used. For >52 weeks, 
a slightly different approach will be followed, where 
multiple time points will be synthesised following avail-
able data. We will make attempts to model a time course 
function for pain scales instead of analysis for multiple 
timeframes, if possible.
Surface under the cumulative ranking curves and prob-
ability ranks will be used to estimate the likelihood of 
individual treatments being superior than the other treat-
ments for the individual with PFP.
Assessing statistical heterogeneity and exploring it with individual 
patient data
Statistical heterogeneity will be assessed by inspecting the 
between study SD, comparing fit of the fixed and random 
effect models. Depending on resources and data avail-
ability, individual patient data from a previous RCT by 
our group will be used together with study level data to 
explore statistical heterogeneity.33 Otherwise, only study 
level data will be used. The following factors are consid-
ered for exploration when sufficient data are available 
(>10 studies/events per variable), in the following order: 
diagnostic approach used (clinical vs imaging), pain 
intensity, symptom duration, active or sedentary popu-
lation, age, sex (male/female), quality of life, unilateral 
versus bilateral pain and publication status (published/
unpublished).34 35
Exploring inconsistency in the network
The consistency assumption will be tested for each 
network. We will compare results from a model that 
assumes consistency with a model that relaxes the consis-
tency assumption to assess whether there is evidence 
of inconsistency. For this purpose, we will compare the 
models’ residual deviance and deviance information 
criterion to examine model fit. If we identify evidence of 
inconsistency, we will use the node-split method to iden-
tify where in the network the inconsistency is.36 We will 
use a Bonferroni correction for interpreting multiple 
p values.
Assessing small study bias
Where possible, we will use comparison-adjusted funnel 
plots to examine small study bias. In this case, we assume 
that small study bias is consistent across comparisons, and 
experimental treatments are more likely to be favoured 
in small studies compared with control treatments/
groups. The funnel plot will be evaluated for its distribu-
tion, where missing small studies are expected favouring 
the control treatment in the presence of small study bias. 
Funnel plots will be generated for each outcome, but only 
when ≥10 studies are available.37 Conventional funnel 
plots for pairwise comparisons are constructed if compar-
ison-adjusted funnel plots cannot be constructed.26
Threshold analysis for credibility of the NMA’s conclusions
Risk of bias in the pair-wise estimates may distort the reli-
ability of the network’s estimate and can, therefore, affect 
the credibility of the NMA’s conclusion. We will investi-
gate if bias in the estimate for global rating of change and 
pain would change the posterior mean treatment effect 
and hence the recommended treatment based on the 
probability ranks.38 We will perform a threshold analysis 
where the variance around the bias estimate is assumed to 
be 0. We assume bias for both measures to overestimate 
or underestimate treatment effects by maximally 20%, 
following empirical estimations of bias by Page et al, Wood 
et al and Armijo-Olivo et al.39–41 The threshold analysis will 
be run with steps of 5% to detect the level at which bias 
may attenuate rankings.
Potential limitations of the planned work
NMA allows multiple interventions to be compared 
simultaneously and can form a coherent basis for inter-
vention recommendations. Notwithstanding this, with 
any evidence synthesis, the quality of the planned work 
is dependent on the availability of study data and the 
comparisons investigated to allow the construction of a 
network. NMA relies on connected networks of evidence; 
it is not possible to make comparisons between interven-
tions that are unconnected. The method assumes that 
the evidence is consistent, so that the intervention effects 
observed directly in head-to-head studies are in agreement 
with those obtained indirectly via the network of compar-
isons. It is therefore essential to check the consistency 
assumption when possible (ie, both direct and indirect 
evidence are available). As with all evidence syntheses, the 
NMA estimates reflect the evidence available including 
the limitations in that evidence. Assessment of risk of bias 
of the included studies is therefore essential. Exploration 
of heterogeneity through subgroup analysis is limited by 
the evidence available with limited power to detect effects 
and may suffer from aggregation bias. There are also 
limitations to the living nature of the proposed research. 
Living reviews are labour intensive and rely on regular 
updates. Moreover, the chance of type 1 errors, that is, 
incorrectly concluding there is a significant effect in 
the meta-analysis, increases with the growing number of 
updates.
Administration, dissemination and updating the living 
systematic review
The living systematic review will be administered at the 
Research Unit for General Practice in Aalborg, and we 
plan to update the NMA for at least 5 years. The study 
started on 1 February 2018, and the expected completion 
date for its first version is 15 January 2019. The search 
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and review process will be updated every 12 months, if 
needed. When new data have become available, we will 
update the analysis and present the updated findings 
at the website of Aalborg University. Here, we will also 
provide a plain language summary for patients and clini-
cians dealing with PFP. If there is a change in conclusions, 
republication will be sought in an international peer-re-
viewed journal. We will seek presentation of the study 
results on national and international conferences, and we 
will submit the full-text report for ‘open access’ publica-
tion in an international peer-reviewed journal.
PErsPECtIvEs
Systematic reviews should inform clinical practice and 
treatment decisions. When multiple treatments exist, 
traditional systematic reviews come shorthanded. NMA is 
the only design that can study the comparative effective-
ness of all available treatments for a condition. Patients 
and clinicians dealing with PFP are in urgent need of 
evidence rather than expert opinion-based guidance 
for the treatment of this often long-living condition. 
NMA will rank treatments according to their proba-
bility of being the most effective treatment. In this way, it 
directly informs the clinician and patient when making a 
shared decision-making on how to treat PFP. The ‘living’ 
nature of this NMA facilitates to make an informed 
shared decision in clinical practice based on the latest 
level 1 evidence.
EthICs And dIssEMInAtIOn
Ethical approval is not required, as this study will be based 
on published data. The study commenced at 1 February 
2018, and its expected completion date is 15 January 2019. 
Full publication of the work will be sought in an interna-
tional peer-reviewed journal, as well as translational arti-
cles to disseminate the work to clinical practitioners.
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